NCT06554184 - HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents | Biotech Hunter

Enrollment

706

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

July 28, 2025

Study Completion Date

September 1, 2025

Conditions

Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Interventions

DRUG

HR20013 + dexamethasone + palonosetron placebo

DRUG

Palonosetron + dexamethasone + HR20013 placebo

Trial Locations (1)

Sun Yat-sen University Cancer Center Yuexiu Campus, Guangzhou

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY